Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Regulatory press release

All conditions for the Subscription Guarantee in Ortivus AB’s ongoing Rights Issue now fulfilled

Ortivus
Download the release

In the press release dated 25 August 2025, it was stated, among other things, that the subscription guarantee provided by Ponderus Invest AB in connection with the ongoing rights issue, as resolved by the Extraordinary General Meeting held on 19 September 2025, was conditional upon the Swedish Inspectorate of Strategic Products (ISP), in accordance with the Act (2023:560) on the Screening of Foreign Direct Investments (FDI), issuing a decision that no review was required, or, if a review were undertaken, approving the investment that could result from the fulfilment of the guarantee.

The ISP has now notified that Ponderus Invest AB’s FDI application does not give rise to any review. Consequently, the subscription guarantee provided by Ponderus Invest AB in respect of the rights issue is no longer subject to any conditions.

Contacts


For further information, please contact

Johan Wewel, CFO

Phone +46 8 446 45 00

About Ortivus


Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process. 
 
Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.

Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company’s Certified Adviser is FNCA Sweden AB.
 
Read more about our solutions at www.ortivus.com

Attachments


All conditions for the Subscription Guarantee in Ortivus AB’s ongoing Rights Issue now fulfilled

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.